1 Abdulkadir, S, Carvalhal, GF, Kaleem, Z et al. 2000 Tissue factor expression and angiogenesis in human prostate carcinoma Hum Pathol 31 443–447.

1 Abdulkadir, S, Carvalhal, GF, Kaleem, Z et al. 2000Tissue factor expression and angiogenesis in human prostate carcinomaHum Pathol31443–447.)| false
• Search Google Scholar
• Export Citation

2 Attard, G, Reid, AH, A’Hern, R et al. 2009 Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742–3748.

2 Attard, G, Reid, AH, A’Hern, R et al. 2009Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerJ Clin Oncol273742–3748.)| false
• Search Google Scholar
• Export Citation

3 Baglin, T 1996 Disseminated intravascular coagulation: diagnosis and treatment BMJ 312 683–687.

3 Baglin, T 1996 Disseminated intravascular coagulation: diagnosis and treatment BMJ 312 683–687.)| false
• Search Google Scholar
• Export Citation

4 Begue, R, Dennehy, PH, Peter, G 1991 Hemolytic uremic syndrome associated with Streptococcus pneumoniae N Engl J Med 325 133.

4 Begue, R, Dennehy, PH, Peter, G1991Hemolytic uremic syndrome associated with Streptococcus pneumoniaeN Engl J Med325133.)| false
• Search Google Scholar
• Export Citation

5 Bern, MM 2005 Coagulopathy, following medical therapy, for carcinoma of the prostate Hematology 10 65–68.

5 Bern, MM 2005 Coagulopathy, following medical therapy, for carcinoma of the prostate Hematology 10 65–68.)| false
• Search Google Scholar
• Export Citation

6 Best, TR, Jenkis, JK, Murphy, FY, et al.JPersistent adrenal insufficiency secondary to low-dose ketoconazole therapy. 82:676–680, 1987.

6 Best, TR, Jenkis, JK, Murphy, FY, et al.JPersistent adrenal insufficiency secondary to low-dose ketoconazole therapy. 82:676–680, 1987.)| false
• Search Google Scholar
• Export Citation

7 Chakrapee-Sirisuk, S, Amornpichetkul, K, Visudhiphan, S et al. 2001 Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review J Med Assoc Thai 84 1495–1501.

7 Chakrapee-Sirisuk, S, Amornpichetkul, K, Visudhiphan, S et al. 2001Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and reviewJ Med Assoc Thai841495–1501.)| false
• Search Google Scholar
• Export Citation

8 Cherin, P, Brivet, F, Tertian, G et al. 1991 Recurrent thrombocytopenic thrombotic purpura associated to prostatic cancer. A case Presse Med 20 1073–1077.

8 Cherin, P, Brivet, F, Tertian, G et al. 1991Recurrent thrombocytopenic thrombotic purpura associated to prostatic cancer. A casePresse Med201073–1077.)| false
• Search Google Scholar
• Export Citation

9 Cines, D, Pollak, ES, Buck, CA et al. 1998 Endothelial cells in physiology and in the pathophysiology of vascular disorders Blood 91 3527–3561.

9 Cines, D, Pollak, ES, Buck, CA et al. 1998Endothelial cells in physiology and in the pathophysiology of vascular disordersBlood913527–3561.)| false
• Search Google Scholar
• Export Citation

10 Fouchardière de la, C, Flechon, A, Droz, JP 2003 Coagulopathy in prostate cancer Neth J Med 61 347–354.

10 Fouchardière de la, C, Flechon, A, Droz, JP2003Coagulopathy in prostate cancerNeth J Med61347–354.)| false
• Search Google Scholar
• Export Citation

11 Duran, I, Tannock, IF 2006 Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer J Gen Intern Med 21 C6–8.

11 Duran, I, Tannock, IF2006Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancerJ Gen Intern Med21C6–8.)| false
• Search Google Scholar
• Export Citation

12 Eichenberger, T, Trachtenberg, J, Toor, P et al. 1989 Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells J Urol 141 190–191.

12 Eichenberger, T, Trachtenberg, J, Toor, P et al. 1989Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cellsJ Urol141190–191.)| false
• Search Google Scholar
• Export Citation

13 Feinberg, JE, Hurwitz, S, Cooper, D et al. 1998 A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group J Infect Dis 177 48–56.

13 Feinberg, JE, Hurwitz, S, Cooper, D et al. 1998A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study GroupJ Infect Dis17748–56.)| false
• Search Google Scholar
• Export Citation

14 Figg, WD, Woo, S, Zhu, W et al. 2010 A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer J Urol 183 2219–2226.

14 Figg, WD, Woo, S, Zhu, W et al. 2010A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancerJ Urol1832219–2226.)| false
• Search Google Scholar
• Export Citation

15 Francis, KK, Kalyanam, N, Terrell, DR et al. 2007 Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases Oncologist 12 11–19.

15 Francis, KK, Kalyanam, N, Terrell, DR et al. 2007Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published casesOncologist1211–19.)| false
• Search Google Scholar
• Export Citation

16 Grignon, D, Turnbull, DI, Lohmann, RC 1986 Carcinoma of the prostate presenting as acute disseminated intravascular coagulation Can Med Assoc J 135 775–776.

16 Grignon, D, Turnbull, DI, Lohmann, RC1986Carcinoma of the prostate presenting as acute disseminated intravascular coagulationCan Med Assoc J135775–776.)| false
• Search Google Scholar
• Export Citation

17 Jensen, JB, Langkilde, NC 2000 Subcutaneous bleeding: first sign of prostate cancer Scand J Urol Nephrol 34 215–216.

17 Jensen, JB, Langkilde, NC2000Subcutaneous bleeding: first sign of prostate cancerScand J Urol Nephrol34215–216.)| false
• Search Google Scholar
• Export Citation

18 Lee, YP, Schwarz, EM, Davies, M et al. 2002 Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model Cancer Res 62 5564–5570.

18 Lee, YP, Schwarz, EM, Davies, M et al. 2002Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse modelCancer Res625564–5570.)| false
• Search Google Scholar
• Export Citation

19 Lim, HY, Agarwal, AM, Agarwal, N et al. 2009 Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer Singapore Med J 50 e178–180.

19 Lim, HY, Agarwal, AM, Agarwal, N et al. 2009Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancerSingapore Med J50e178–180.)| false
• Search Google Scholar
• Export Citation

20 McKechnie, J 1989 Prostatic carcinoma presenting as a haemorrhagic diathesis after dental extraction Br Dent J 166 295–296.

20 McKechnie, J 1989 Prostatic carcinoma presenting as a haemorrhagic diathesis after dental extraction Br Dent J 166 295–296.)| false
• Search Google Scholar
• Export Citation

21 Mechtcheriakova, D, Wlachos, A, Holzmüller, H et al. 1999 Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1 Blood 93 3811–3823.

21 Mechtcheriakova, D, Wlachos, A, Holzmüller, H et al. 1999Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1Blood933811–3823.)| false
• Search Google Scholar
• Export Citation

22 Moll, T, Czyz, M, Holzmüller, H et al. 1995 Regulation of the tissue factor promoter in endothelial cells. Binding of NF kappa B-, AP-1-, and Sp1-like transcription factors J Biol Chem 270 3849–3857.

22 Moll, T, Czyz, M, Holzmüller, H et al. 1995Regulation of the tissue factor promoter in endothelial cells. Binding of NF kappa B-, AP-1-, and Sp1-like transcription factorsJ Biol Chem2703849–3857.)| false
• Search Google Scholar
• Export Citation

23 Ngo, LS, Yeo, A, Wong, AS et al. 2007 Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Ann Acad Med Singapore 36 811–914.

23 Ngo, LS, Yeo, A, Wong, AS et al. 2007Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, SingaporeAnn Acad Med Singapore36811–914.)| false
• Search Google Scholar
• Export Citation

24 Palumbo, JS, Talmage, KE, Massari, JV et al. 2005 Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells Blood 105 178–185.

24 Palumbo, JS, Talmage, KE, Massari, JV et al. 2005Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cellsBlood105178–185.)| false
• Search Google Scholar
• Export Citation

25 Pont, A, Williams, PL, Azhar, S et al. 1982 Ketoconazole blocks testosterone synthesis Arch Intern Med 142 2137–2140.

25 Pont, A, Williams, PL, Azhar, S et al. 1982Ketoconazole blocks testosterone synthesisArch Intern Med1422137–2140.)| false
• Search Google Scholar
• Export Citation

26 Sallah, S, Wan, JY, Nguyen, NP et al. 2001 Disseminated intravascular coagulation in solid tumors: clinical and pathologic study Thromb Haemost 86 828–833.

26 Sallah, S, Wan, JY, Nguyen, NP et al. 2001Disseminated intravascular coagulation in solid tumors: clinical and pathologic studyThromb Haemost86828–833.)| false
• Search Google Scholar
• Export Citation

27 Scholz, M, Jennrich, R, Strum, S et al. 2005 Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone J Urol 173 1947–1952.

27 Scholz, M, Jennrich, R, Strum, S et al. 2005Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisoneJ Urol1731947–1952.)| false
• Search Google Scholar
• Export Citation

28 Small, EJ, Halabi, S, Dawson, NA et al. 2004 Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol 22 1025–1033.

28 Small, EJ, Halabi, S, Dawson, NA et al. 2004Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)J Clin Oncol221025–1033.)| false
• Search Google Scholar
• Export Citation

29 Spector, JI, Zimbler, H 1987 Carcinoma of the prostate presenting as acute disseminated intravascular coagulation Can Med Assoc J 136 570.

29 Spector, JI, Zimbler, H1987Carcinoma of the prostate presenting as acute disseminated intravascular coagulationCan Med Assoc J136570.)| false
• Search Google Scholar
• Export Citation

30 Staton, CA, Brown, NJ, Lewis, CE 2003 The role of fibrinogen and related fragments in tumour angiogenesis and metastasis Exp Opin Biol Ther 3 1105–1120.

30 Staton, CA, Brown, NJ, Lewis, CE2003The role of fibrinogen and related fragments in tumour angiogenesis and metastasisExp Opin Biol Ther31105–1120.)| false
• Search Google Scholar
• Export Citation

31 Whang, PG, Schwarz, EM, Gamradt, SC et al. 2005 The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone J Orthop Res 23 1475–1483.

31 Whang, PG, Schwarz, EM, Gamradt, SC et al. 2005The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in boneJ Orthop Res231475–1483.)| false
• Search Google Scholar
• Export Citation

32 Wojtukiewicz, MZ, Sierko, E, Rak, J 2004 Contribution of the hemostatic system to angiogenesis in cancer Semin Thromb Hemost 30 5–20.

32 Wojtukiewicz, MZ, Sierko, E, Rak, J2004Contribution of the hemostatic system to angiogenesis in cancerSemin Thromb Hemost305–20.)| false
• Search Google Scholar
• Export Citation

33 Yi, B, Williams, PJ, Niewolna, M et al. 2002 Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer Cancer Res 62 917–923.

33 Yi, B, Williams, PJ, Niewolna, M et al. 2002Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancerCancer Res62917–923.)| false
• Search Google Scholar
• Export Citation